UKRI Budget 2025–26: Applied Research and the UK Commercialisation Gap
Field notes on the UKRI budget 2025-26, the new funding buckets, impact rhetoric, and why the UK still exports too many of its best ideas.
What’s New in the UKRI Budget?
According to DSIT, its overall R&D budget for 2025–26 is £13.9 billion, within a wider £20.4 billion of public R&D across government. Of that, UKRI receives £8.8 billion, sustaining what ministers describe as “record levels” of investment in the research and innovation system. The headline numbers are set out in the
allocations document.
UKRI then slices this into three broad priorities: protecting a strong base of curiosity‑driven research, supporting strategic government and societal missions, and targeting innovation, company scale‑up and growth. The detail is laid out in UKRI’s PDF budget allocations explainer, which shows how much goes to each research council, Research England, Innovate UK, cross‑UKRI funds and collective talent programmes.
In simple terms, that means a mix of core council budgets (AHRC through to STFC), a large Research England block grant, Innovate UK’s innovation funding, and a substantial pot of cross‑cutting money for infrastructure and thematic programmes that are meant to connect research, innovation and economic impact rather than leave them in separate lanes.
From World‑Class Research to Weak Commercialisation
On the research side, the UK still looks strong by international standards. The government’s own International comparison of the UK research base 2025 shows that the UK accounts for about 6% of global publications but a much higher share of the top 1% most highly cited work, with a field‑weighted citation impact that remains near the top of the G7. The problem is what happens next. Various innovation reports and sector analyses point out that the UK underperforms when it comes to turning this science base into large, R&D‑intensive firms, manufacturing value‑added and exports.
Technologies developed in UK universities are too often scaled, manufactured and monetised elsewhere, leaving the UK acting as the brains of other people’s industrial strategies rather than the engine of its own. That’s a theme explored in more depth in this earlier field note on UK science and commercialisation. UKRI now foregrounds research commercialisation much more clearly – with dedicated pages on commercialising research and new proof‑of‑concept and project funding routes – but at the macro level the diagnosis is familiar: world‑class research performance, patchy domestic capture of the economic value that flows from it.
How the UKRI Budget 2025–26 Tries to Close the Commercialisation Gap
The redesigned budget architecture is supposed to make it easier to follow an idea from curiosity‑driven research through to mission‑oriented programmes and into innovation and commercialisation support. Cross‑UKRI funding for infrastructure, translation and shared programmes is meant to cut across council boundaries and reduce the friction between grant‑funded research and the later stages of deployment and scale‑up.
DSIT explicitly frames the settlement as protecting core science while pushing more money into strategic priorities such as clean energy, security, digital and data, engineering biology and advanced manufacturing. The allocations document emphasises that each pound of public R&D is expected to leverage several pounds of private investment over time – a key part of the political case for maintaining spend in a tight fiscal environment.
Alongside this, UKRI highlights collective talent schemes and Innovate UK programmes designed to support people and firms at different stages of the commercialisation journey, from proof‑of‑concept through to late‑stage development. On paper, at least, the UKRI budget 2025–26 is now framed around the full pipeline from discovery to deployment, rather than treating those stages as separate worlds.
Will Budget Architecture Shift Culture?
The awkward truth is that changing budget diagrams is easier than changing culture. Universities still largely reward being cited, not being manufactured. The safest academic career path is usually another paper and another grant, not a risky spin‑out that might fail. Capital markets, procurement rules and regulatory pathways all add extra drag to the journey from lab to market.
The National Audit Office, in its recent overview of DSIT and UKRI, has already questioned whether the current grant‑based model is delivering fully on the government’s ambitions for growth and productivity. That scrutiny is part of the backdrop to this more tightly framed remit for UKRI, where “impact” is now read as growth, jobs and strategic capability as much as citations and case‑study narratives.
The real test for this applied research pivot will be whether, a few years down the line, the UK can point not just to strong publication metrics but to a thicker pipeline of home‑grown, R&D‑intensive companies and manufacturing activity that owe their existence to this new way of structuring the UKRI budget – rather than to someone else’s incentives in another jurisdiction.
The UKRI settlement will influence technology scale-up only if public funding connects technical progress to customers, infrastructure and follow-on capital. Capital availability is one of the Seven Barriers, but the quality and sequencing of that capital matter as much as its total volume. Grants can reduce early technical risk; they cannot substitute indefinitely for procurement, private investment or repeatable revenue. The commercialisation test is whether funded programmes create evidence that makes the next stage financeable on progressively stronger market terms.
A Field Note from the Commercialisation Gap
From the coalface of fleet decarbonisation, infrastructure builds and deep‑tech start‑ups, this all feels like overdue plumbing work in a system that has been leaking value for decades. The UK has no shortage of ideas or talent; what it lacks is reliable, repeatable routes from lab bench to loading bay that are financed and governed on UK terms.
If the UKRI budget 2025–26 and its successors really do make it easier to join up research councils, infrastructure, Innovate UK support and patient capital, there is at least a chance to shift the UK from “world‑class research, weak commercialisation” to something more balanced. That will also depend on whether other parts of the policy stack – skills, STEM education and regional innovation support – move in the same direction, a theme picked up in this piece on the UK’s innovation and STEM policy fixes.
